摘要
目的研究玻璃体腔注射雷珠单抗(IVR)治疗有临床意义的黄斑水肿(CSME)及非临床意义的黄斑水肿(NCSME)患者的临床效果。方法将糖尿病黄斑水肿(DME)的患者77例,分为CSME组及NCSME组,行IVR治疗,比较治疗前后患者的最佳矫正视力(BCVA)和黄斑水肿最高高度。结果两组治疗1个月后,BCVA较治疗前差异均有统计学意义(P<0.05)。两组间比较,治疗前后各时间点黄斑水肿最高高度差异均无统计学意义(P>0.05)。结论 CSME及NCSME患者行IVR治疗后黄斑水肿高度降低,但黄斑水肿高度不能完全反映患者视力情况。
Objective To explore the clinical efficacy of clinically significant macular edema（ CSME） and non-clinically significant macular edema（ NCSME） treated with Ranibizumab intravitreal injection. Methods A total of 77 BRVO-ME cases were divided into 2 groups： CSME group（ n = 51） and NCSME group（ n = 26）. The two groups received Ranibizumab intravitreal injection. Best corrected visual acuity（ BCVA） and highest thickness of macular edema of the two groups were observed. Results One months after treatment,BCVA of the two groups were improved（ P〈0. 05）. No significant difference between two groups was found in the highest thickness of macular edema（ P〉0. 05）. Conclusion Ranibizumab intravitreal injection can improve visual acuity and reduce the highest thickness of macular edema in patients with CSME and NCSME. The highest thickness of macular edema can not completely reflect the visual acuity.
出处
《山东大学耳鼻喉眼学报》
CAS
2017年第2期96-98,共3页
Journal of Otolaryngology and Ophthalmology of Shandong University
关键词
糖尿病性黄斑水肿
最高高度
最佳矫正视力
雷珠单抗
Diabetic macular edema
Highest thickness
Best corrected visual acuity
Ranibizumab
